Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Announces Filing of Its Annual Report on Form 10-K
Argos Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Argos Therapeutics Added to Russell 2000(R) and 3000(R) Indexes